Biomerica Inc 10-Q for FY2020 Q3
Biomerica Inc (BMRA)
About this 10-Q
Biomerica Inc filed this 10-Q on April 14, 2020, covering the quarter ended February 29, 2020 (FY2020 Q3).
Headline figures
Quarter ended February 29, 2020, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $1.18M
- down 6.7% from $1.26M a year earlier
- Net loss
- $860.93K
- compared with a net loss of $678.75K a year earlier
- Diluted EPS
- -$0.09
- compared with -$0.07 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2020
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 0-8765
BIOMERICA, INC.
--------------------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 95-2645573
--------------------------------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
17571 Von Karman Avenue, Irvine, CA 92614
--------------------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number including area code: (949) 645-2111
--------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since last report.)
(TITLE OF EACH CLASS) (NAME OF EACH EXCHANGE ON WHICH REGISTERED)
--------------------- -------------------------------------------
Common, par value $.08 NASDAQ Capital Market
Securities registered pursuant to Section 12(g) of the Act:
(TITLE OF EACH CLASS)
COMMON STOCK, PAR VALUE $0.08
Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [_]
Indicate by check mark whether the registrant is a large accelerated, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer [_] Accelerated Filer [_]
Non-Accelerated Filer [_] Smaller Reporting Company [X]
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [_] No [X]
Indicate the number of shares outstanding of each of the registrant's common stock, as of the latest practicable date: 11,305,190 shares of common stock, par value $0.08, as of April 14, 2020.
| BIOMERICA, INC. | ||
| INDEX | ||
| PART I | Financial Information | |
| Item 1. | Financial Statements: | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) – Three and Nine Months Ended | 1 | |
| Condensed Consolidated Balance Sheets (unaudited) February 29, 2020 and (audited) May 31, 2019 | 2 | |
| Consolidated Statements of Shareholders’ Equity (unaudited)- Nine months ended February 29, 2020 | 3 | |
|
| Condensed Consolidated Statements of Cash Flows (unaudited) - Nine months ended February 29, 2020 and February 28, 2019 | 4 |
|
|
|
|
| Notes to Condensed Consolidated Financial Statements (unaudited) | 5-13 | |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 14-17 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 17 |
| Item 4. | Controls and Procedures | 17 |
| PART II | Other Information | |
| Item 1. | Legal Proceedings | 17 |
| Item 1A. | Risk Factors | 17 |
| Item 2. | Unregistered Sales of Equity Securities & Use of Proceeds | 19 |
| Item 3. | Defaults upon Senior Securities | 19 |
| Item 4. | Mine Safety Disclosures | 19 |
| Item 5. | Other Information | 19 |
| Item 6. | Exhibits | 19 |
|
| Signatures | 20 |
| PART I - FINANCIAL INFORMATION SUMMARIZED FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS | |||||||||||
| BIOMERICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) | |||||||||||
|
Nine Months Ended |
Three Months Ended | ||||||||||
|
| February 29, 2020 | February 28, 2019 | February 29, 2020 | February 28, 2019 | |||||||
| Net sales | $ | 3,967,712 |
| $ | 4,034,822 |
| $ | 1,176,889 |
| $ | 1,261,161 |
| Cost of sales |
| (2,919,557) |
| (2,923,615) |
| (964,910) |
| (895,237) | |||
| Gross profit |
| 1,048,155 |
|
| 1,111,207 |
|
| 211,979 |
|
| 365,924 |
| Operating Expense: |
|
|
|
|
|
|
|
|
|
|
|
| Selling, general and administrative | 1,714,543 | 1,488,890 | 653,585 | 576,070 | |||||||
| Research and development |
| 1,248,599 |
|
| 1,270,288 |
|
| 473,279 |
|
| 497,102 |
| Total operating expenses |
| 2,963,142 |
| 2,759,178 |
| 1,126,864 |
| 1,073,172 | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss from operations |
| (1,914,987) |
| (1,647,971) |
| (914,885) |
| (707,248) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other Income (Expense): | |||||||||||
| Dividend and interest income |
| 62,515 |
|
| 40,288 |
|
| 53,964 |
|
| 28,502 |
| Interest expense |
| (10) |
| (47) |
| (5) |
| -- | |||
| Total other income |
| 62,505 |
|
| 40,241 |
|
| 53,959 |
|
| 28,502 |
| Net loss | $ | (1,852,482) |
| $ | (1,607,730) |
| $ | (860,926) |
| $ | (678,746) |
| Basic net loss per common share | $ | (0.19) | $ | (0.18) | $ | (0.09) | $ | (0.07) | |||
| Diluted net loss per common share | $ | (0.19) |
| $ | (0.18) |
| $ | (0.09) |
| $ | (0.07) |
| Weighted average number of common and |
|
|
|
|
|
|
|
|
| ||
| Basic |
| 9,882,459 |
| 9,103,225 |
| 9,814,504 |
| 9,322,549 | |||
| Diluted |
| 9,882,459 |
|
| 9,103,225 |
|
| 9,814,504 |
|
| 9,322,549 |
| Net loss | $ | (1,852,482) |
|
| (1,607,730) |
| $ | (860,926) |
| $ | (678,746) |
| Other comprehensive loss, net of tax: |
|
|
|
|
|
|
|
|
|
|
|
| Foreign currency translation |
| (4,157) |
| (7,385) |
| (928) |
| (1,579) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Comprehensive loss | $ | (1,856,639) | $ | (1,615,115) | $ | (861,854) | $ | (680,325) | |||
| The accompanying notes are an integral part of these statements. | |||||||||||
1
| BIOMERICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
|
| February 29, 2020 (unaudited) | May 31, 2019 (audited) | |||
|
| |||||
| Assets |
|
|
|
|
|
| Current Assets: |
|
|
|
|
|
| Cash and cash equivalents | $ | 2,391,732 | $ | 686,785 | |
| Accounts receivable, less allowance for doubtful accounts of $76,681 and $73,110 as of February 29, 2020 and May 31, 2019, respectively |
|
962,321 |
|
|
1,454,652 |
| Inventories, net | 2,187,605 | 2,151,090 | |||
| Prepaid expenses and other |
| 197,505 |
|
| 202,402 |
| Total current assets | 5,739,163 | 4,494,929 | |||
|
|
|
|
|
|
|
| Property and Equipment, net of accumulated depreciation and amortization of $1,688,685 and $1,762,344 as of February 29, 2020 and May 31, 2019, respectively | 301,153 | 351,070 | |||
|
|
|
|
|
|
|
| Right of Use Assets, net of amortization | 1,767,938 | -- | |||
|
|
|
|
|
|
|
| Investments | 165,324 | 165,324 | |||
|
|
|
|
|
|
|
| Intangible Assets, net | 114,011 | 107,209 | |||
|
|
|
|
|
|
|
| Other Assets |
| 127,521 |
| 126,832 | |
| Total Assets | $ | 8,215,110 |
| $ | 5,245,364 |
| Liabilities and Shareholders' Equity |
|
|
|
|
|
| Current Liabilities: |
|
|
|
|
|
| Accounts payable and accrued expenses | $ | 1,267,662 | $ | 1,037,565 | |
| Accrued compensation |
| 236,043 |
|
| 226,829 |
| Equity financing deposit-officer |
| 200,000 |
| -- | |
| Lease liability, current portion |
| 206,127 |
|
| -- |
|
|
|
|
|
|
|
| Total current liabilities |
| 1,909,832 |
|
| 1,264,394 |
| Lease Liability, net of current portion |
| 1,624,358 |
|
| -- |
|
|
|
|
|
|
|
| Total Liabilities |
| 3,534,190 |
|
| 1,264,394 |
|
|
|
|
|
|
|
| Commitments and Contingencies (Note 6 and 7) |
|
|
|
|
|
| Shareholders' Equity: |
|
|
|
|
|
| Preferred stock, Series A 5% convertible, $0.08 par value, 571,429 shares authorized, issued and outstanding at February 29, 2020 and no shares authorized, issued and outstanding at May 31 2019 |
|
45,714 |
|
|
-- |
| Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at February 29, 2020 and none at May 31, 2019, respectively and none issued and outstanding at February 29, 2020 and May 31, 2019 |
| -- |
|
| -- |
| Common stock, $0.08 par value authorized 25,000,000 shares, issued and outstanding 10,310,355 and 9,677,188 at February 29, 2020 and May 31, 2019, respectively | |||||
| 824,827 | 774,173 | ||||
| Additional paid-in-capital |
| 26,446,538 |
|
| 22,830,006 |
| Common stock subscribed | (1,156,311) | -- | |||
| Accumulated other comprehensive loss |
| (40,688) |
|
| (36,531) |
| Accumulated deficit |
| (21,439,160) |
|
| (19,586,678) |
|
|
|
|
|
|
|
| Total Shareholders' Equity |
| 4,680,920 |
| 3,980,970 | |
|
|
|
|
|
|
|
| Total Liabilities and Shareholders' Equity | $ | 8,215,110 |
| $ | 5,245,364 |
| The accompanying notes are an integral part of these statements | |||||
2
| BIOMERICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) Nine Months Ended February 29, 2020 | ||||||||||||||||||||||||
| Additional Paid-in Capital | ||||||||||||||||||||||||
| Common Stock | Series A 5% Preferred Stock | Subscriptions Receivable | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total | |||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||
| Balances, May 31, 2019 | 9,677,188 |
| $ | 774,173 |
| -- |
| $ | -- |
| $ | 22,830,006 |
| $ | -- |
| $ | (36,531) |
| $ | (19,586,678) |
| $ | 3,980,970 |
| Exercise of stock options | 80,375 |
|
| 6,430 |
| -- |
|
| -- |
|
| 73,398 |
|
| -- |
|
| -- |
|
| -- |
|
| 79,828 |
| Net proceeds | 552,792 |
|
| 44,224 |
| -- |
|
| -- |
|
| 1,478,345 |
|
| (1,156,311) |
|
| -- |
|
| -- |
|
| 366,258 |
| Issuance of preferred stock | -- |
|
| -- |
| 571,429 |
|
| 45,714 |
|
| 1,871,872 |
|
| -- |
|
| -- |
|
| -- |
|
| 1,917,586 |
| Foreign currency translation | -- |
|
| -- |
| -- |
|
| -- |
|
| -- |
|
| -- |
|
| (4,157) |
|
| -- |
|
| (4,157) |
| Compensation expense in connection with options granted | -- |
|
| -- |
| -- |
|
| -- |
|
| 192,917 |
|
| -- |
|
| -- |
|
| -- |
|
| 192,917 |
| Net loss | -- |
|
| -- |
| -- |
|
| -- |
|
| -- |
|
| -- |
|
| -- |
|
| (1,852,482) |
|
| (1,852,482) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Balances, February 29, 2020 | 10,310,355 |
| $ | 824,827 |
| 571,429 |
| $ | 45,714 |
| $ | 26,446,538 |
| $ | (1,156,311) |
| $ | (40,688) |
| $ | (21,439,160) |
| $ | 4,680,920 |
| The accompanying notes are an integral part of these statements. | ||||||||||||||||||||||||
3
| BIOMERICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | |||||
|
| Nine Months Ended | ||||
|
| February 29, 2020 | February 28, 2019 | |||
| Cash flows from operating activities: |
|
|
|
|
|
| Net loss | $ | (1,852,482) |
| $ | (1,607,730) |
| Adjustments to reconcile net loss to net cash used in |
|
|
|
|
|
| Depreciation and amortization | 94,772 | 128,114 | |||
| Change in provision for allowance on accounts receivable |
| 3,571 |
|
| 13,192 |
| Inventory reserve | 5,684 | 7,249 | |||
| Stock option expense |
| 192,917 |
|
| 146,514 |
| Reduction (increase)_ in deferred rent liability | (37,971) | 5,360 | |||
| Amortization of right-of-use asset |
| 213,032 |
|
| -- |
| Changes in assets and liabilities: | |||||
| Accounts receivable |
| 488,759 |
|
| (290,727) |
| Inventories | (42,199) | 91,244 | |||
| Prepaid expenses and other |
| 4,898 |
|
| 46,772 |
| Reduction in lease liability | (150,485) | -- | |||
| Other assets |
| (689) |
|
| (8,984) |
| Accounts payable and accrued expenses | 268,068 | 197,386 | |||
| Accrued compensation |
| 9,214 |
|
| 13,902 |
| Net cash used in operating activities |
| (802,911) |
|
| (1,257,708) |
| Cash flows from investing activities: |
|
|
|
|
|
| Increase in intangibles | (23,933) | (46,226) | |||
| Purchases of property and equipment |
| (27,724) |
|
| (72,947) |
| Net cash used in investing activities |
| (51,657) |
|
| (119,173) |
| Net cash flows from financing activities: |
|
|
|
|
|
| Proceeds from sales of common stock, net | 366,258 | 1,011,636 | |||
| Proceeds from sale of convertible preferred stock, net |
| 1,917,586 |
|
| -- |
| Proceeds from exercise of stock options | 79,828 | 82,990 | |||
| Proceeds from equity financing-officer |
| 200,000 |
|
| -- |
| Common stock subscribed |
| -- |
| 2,672 | |
|
|
|
|
|
|
|
| Net cash provided by financing activities |
| 2,563,672 |
| 1,097,298 | |
|
|
|
|
|
|
|
| Effect of exchange rate changes in cash |
| (4,157) |
| (7,385) | |
|
|
|
|
|
|
|
| Net increase (decrease) in cash and cash equivalents | 1,704,947 | (286,968) | |||
|
|
|
|
|
|
|
| Cash and cash equivalents at beginning of period |
| 686,785 |
| 1,204,903 | |
|
|
|
|
|
|
|
| Cash and cash equivalents at end of period | $ | 2,391,732 | $ | 917,935 | |
|
|
|
|
|
|
|
| Supplemental Disclosure of Cash-Flow Information: | |||||
| Cash paid during the period for: |
|
|
|
|
|
| Interest | $ | 9 | $ | 47 | |
| Income taxes | $ | 12,170 |
| $ | -- |
| Non-cash Investing and Financing Activities: |
|
|
|
|
|
| Establishment of Right-of-Use Asset per ASC 842 | $ | 1,942,999 | $ | -- | |
| Establishment of Lease Liability per ASC 842 | $ | 1,980,970 |
| $ | -- |
| The accompanying notes are an integral part of these statements. | |||||
4
BIOMERICA, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Note 1: Basis of Presentation
Biomerica, Inc. and Subsidiaries (collectively "the Company") are primarily engaged in the development, manufacture and marketing of medical diagnostic products.
The Company develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and other medical conditions. The Company’s medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point of care (physicians' offices and over-the-counter drugstores). The diagnostic test kits are used to analyze blood, urine or fecal samples from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations.
The information set forth in these condensed consolidated statements is unaudited and reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of the consolidated results of operations of Biomerica, Inc. and subsidiaries (collectively the “Company”), for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. All adjustments that were made are of a normal recurring nature.
The unaudited Condensed Consolidated Financial Statements and notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in our annual financial statements and notes. The condensed consolidated balance sheet data as of May 31, 2019 was derived from audited financial statements. The accompanying interim condensed consolidated financial statements should be read in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on August 29, 2019 for the fiscal year ended May 31, 2019. The results of operations for our interim periods are not necessarily indicative of results to be achieved for our full fiscal year.
Note 2: Significant Accounting Policies
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Biomerica, Inc. as well as the Company’s German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.
Accounting Estimates
The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the reserve for bad debt, which is estimated based on current as well as historical data with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory reserves, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates.
Concentration of Credit Risk
The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. The Company does not believe it is exposed to significant credit risks.
The Company provides credit in the normal course of business to customers throughout the United States and foreign markets. At February 29, 2020 and May 31, 2019, the Company had two customers which accounted for 52.7% and two customers which accounted for 68.1%, respectively, of gross accounts receivable. The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. The Company had one customer which accounted for approximately 43.4% and 46.8%, of consolidated sales for the nine months ended February 29, 2020 and February 28, 2019, respectively.
5
For the nine months ended February 29, 2020 and February 28, 2019, two vendors accounted for approximately 32.8% and 33.4%, of the purchases of raw materials, respectively. At February 29, 2020 and May 31, 2019 there were two companies which accounted for 46.1% and one company which accounted for 32.1% of accounts payable, respectively.
Cash and Cash Equivalents
Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.
Accounts Receivable
The Company extends unsecured credit to its customers on a regular basis. International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured.
Occasionally certain long-standing customers, who routinely place large orders, will have unusually large accounts receivables balances relative to the total gross accounts receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.
Inventories
The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the Company’s production facilities.
The approximate balances of inventories are the following at:
| February 29, 2020 | May 31, 2019 | ||||
| Raw materials | $ | 1,102,000 |
| $ | 1,208,000 |
| Work in progress | 900,000 | 771,000 | |||
| Finished products |
| 186,000 |
|
| 172,000 |
| Total | $ | 2,188,000 | $ | 2,151,000 | |
Reserves for inventory obsolescence are increased as necessary to reduce obsolete inventory to estimated realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of February 29, 2020 and May 31, 2019, inventory reserves were approximately $55,000 and $49,000, respectively.
Property and Equipment, net
Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation or amortization is removed from the accounts, and gains or losses from retirements and dispositions are credited or charged to income.
Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment and leasehold improvements amounted to $23,822 and $22,436 for the three months ended February 29, 2020 and February 28, 2019, respectively, and $77,641 and $78,118 for the nine months ended February 29, 2020 and February 28, 2019, respectively.
6
Intangible Assets, net
Intangible assets include trademarks, product rights, licenses, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”) 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, licenses, and 17 years for patents. Amortization amounted to $5,405 and $16,666 for the three months ended February 29, 2020 and February 28, 2019, respectively, and $17,131 and $49,996 for the nine months ended February 29, 2020 and February 28, 2019, respectively.
Share-Based Compensation
The Company follows the guidance of the accounting provisions of ASC 718 Share-based Compensation (“ASC 718“), which requires the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (options). The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term, and the risk-free interest rate.
Expected volatilities are based on weighted averages of the historical volatility of the Company’s stock and other factors estimated over the expected term of the options. The expected forfeiture rate is based on historical forfeitures experienced. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term as historically the Company had limited activity surrounding its options. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.
The Company has not paid dividends historically and does not expect to pay them in the future.
The following summary presents the options and warrants granted, exercised, expired, cancelled and outstanding as of February 29, 2020:
| Exercise Price Weighted Average | ||||
|
| Option Shares | |||
|
| ||||
| Outstanding May 31, 2019 | 1,476,209 |
| $ | 2.07 |
| Granted | 356,000 | $ | 2.79 | |
| Exercised | (80,375) |
| $ | 1.01 |
| Cancelled or expired | (47,500) | $ | 3.25 | |
| Outstanding February 29, 2020 | 1,704,334 |
| $ | 2.24 |
During the nine months ended February 29, 2020, options to purchase 80,375 shares of common stock were exercised at prices ranging from $0.82 to $1.20 per share. Proceeds to the Company were approximately $79,828. During the nine months ended February 29, 2020, the Company granted 356,000 options to purchase common stock at an average purchase price of $2.79.
Revenue Recognition
The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, at which point title passes. Revenue is recognized only when collectability is reasonably assured. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In conjunction with sales to certain customers, the Company provides free products upon attaining certain levels of purchases by the customer. The Company accounts for these free products as zero sales and recognizes the cost of the product as part of cost of sales. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volume. The Company evaluated the status of these contracts as of February 29, 2020 and does not believe that any additional discounts will be earned through the end of fiscal 2020 or through the end of the contract periods.
7
Disaggregation of revenue:
The following is a breakdown of revenues according to markets to which the products are sold:
| Nine Months ended | Three Months ended | ||||||||||
| February 29, | February 28, | February 29, | February 28, | ||||||||
| Clinical lab | $ | 2,769,000 |
| $ | 3,150,000 |
| $ | 723,000 |
| $ | 1,043,000 |
| OTC | 778,000 | 653,000 | 271,000 | 131,000 | |||||||
| Physicians’ office |
| 157,000 |
|
| 142,000 |
|
| 32,000 |
|
| 48,000 |
| Contract Manufacturing |
| 264,000 |
| 90,000 |
| 151,000 |
| 39,000 | |||
| Total | $ | 3,968,000 |
| $ | 4,035,000 |
| $ | 1,177,000 |
| $ | 1,261,000 |
See note 5 for additional information regarding revenue concentrations.
Investments
From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value to be less than the fair value. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical devices. The Company owns approximately 6% of the investee, and accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.
Shipping and Handling Fees and Costs
Shipping and handling fees billed to customers are required to be classified as net sales, and shipping and handling costs are required to be classified as either cost of sales or disclosed in the notes to the consolidated financial statements. The Company included shipping and handling fees billed to customers in net sales. The Company included shipping and handling costs associated with inbound freight and unreimbursed shipping to customers in cost of sales.
Research and Development
Research and development costs are generally expensed as incurred.
Income Taxes
The Company has provided a valuation allowance on deferred income tax assets of approximately $2,821,000 and $2,459,000 as of February 29, 2020 and May 31, 2019, respectively.
Foreign Currency Translation
The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the quarter, and revenues and costs are translated using average exchange rates for the quarter. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss.
Lease Liability
Incentive payments received from landlords was recorded as deferred lease incentives and were amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company established a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. During the period ended February 29, 2020, the Company adopted ASC 842, Leases. As a result, the existing deferred rent liability was netted against the Right of Use Asset which was capitalized at that time.
8
In February 2016, the Financial Accounting Standards Board issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. Leases will be classified as financing or operating which will drive the expense recognition pattern. For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively. The Company has elected to exclude short-term leases. The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method. As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 6 – Leases. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term.
Net Loss Per Share
Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options using the treasury stock method. The total amount of anti-dilutive options not included in the earnings per share calculation for the three and nine months ended February 29, 2020 was 476,358 and 483,658, respectively. The total amount of anti-dilutive options not included in the earnings per share calculation for the three and nine months ended February 28, 2019 was 393,865 and 592,080, respectively.
The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted loss per share computations.
| Nine Months Ended | Three Months Ended | ||||||||||
| February 29, |
| February 28, | February 29, |
| February 28, | ||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||
| Numerator: |
|
|
|
|
|
|
|
|
|
|
|
| Net loss | $ | (1,852,482) | $ | (1,607,730) | $ | (860,926) | | ($678,746) | |||
| Denominator for basic loss |
| 9,882,459 |
|
| 9,103,225 |
|
| 9,814,504 |
|
| 9,322,549 |
| Effect of dilutive securities: | |||||||||||
| Options and warrants |
| -- |
|
| -- |
|
| -- |
|
| -- |
| Denominator for diluted loss | 9,882,459 | 9,103,225 | 9,814,504 | 9,322,549 | |||||||
| Basic net loss per common share | $ | (0.19) |
| $ | (0.18) |
| $ | (0.09) |
| $ | (0.07) |
| Diluted net loss per common share | $ | (0.19) | $ | (0.18) | $ | (0.09) | $ | (0.07) | |||
9
New Accounting Pronouncements
On February 15, 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-02, “Reclassification of Certain Tax Effects From Accumulated Comprehensive Income” (“ASU 2018-02”). ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income (“ASCI”) to retained earnings. ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Management is taking the provisions of this statement into account in the preparation of the financial statements for the nine months ended February 29, 2020. The adoption of this standard has not had a significant impact on the Company’s financial statements.
On June 20, 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). ASU 2018-07 was effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. During the nine months ended February 29, 2020 the Company adopted the provisions of this statement and is taking them into account in the preparation of the financial statements for the nine months ended February 29, 2020. The adoption of this standard has not had a significant impact on the Company’s financial statements.
Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.
Note 3: Accounts Payable and Accrued Expenses
The Company’s accounts payable and accrued expenses consist of the following at:
|
| February 29, 2020 | May 31, 2019 | |||
| Accounts payable | $ | 1,267,662 |
| $ | 999,593 |
| Deferred rent |
| -- |
| 37,972 | |
| Total | $ | 1,267,662 |
| $ | 1,037,565 |
As described in the Company’s Form S-3 Registration Statement and Prospectus filed on June 30, 2017 and December 4, 2017, respectively, the Company entered into an At Market Issuance Sales Agreement, whereby, the Company may raise additional working capital and funds for continued development of current research projects. During the quarter that ended February 29, 2020, the Company received $58,572 in net proceeds from the sale of its common stock through this Agreement (including $15,583 from a subscription receivable as of November 30, 2019). The Company also recorded a subscription receivable during the quarter in the net amount of $1,156,311 for sales of common stock but which proceeds were not received until after February 29, 2020. During the nine months ended February 29, 2020, the Company received $366,258 in net proceeds from the sale of its common stock through this Agreement as well as a subscription receivable of $1,156,311, as described above.
On February 26,2020, Biomerica, Inc. issued stock under a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Palm Global Small Cap Master Fund LP (“Palm”) pursuant to which the Company issued 571,429 shares of the Company’s Series A 5% Convertible Preferred Stock, for a purchase price of approximately $2 million, or $3.50 per Series A 5% Convertible Preferred share. The Company incurred approximately $82,000 in issuance costs associated with this stock purchase. The issuance and sale of the Series A 5% Convertible Preferred shares was a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
The Stock Purchase Agreement contains certain anti-dilutive provisions for Palm until the third anniversary. In addition, the Company entered into a Registration Rights Agreement wherein the Company agreed to register for resale with the Securities and Exchange Commission the shares of common stock, $0.08 par value per share, issuable upon conversion of the Series A 5% Convertible Preferred Shares based on certain conditions.
10
The Series A 5% Convertible Preferred Shares are convertible at the option of the holder at any time into an equal number of common stock shares (“Conversion Shares”). The conversion price may be adjusted for stock splits or other common stock issuances. The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred shares if the closing sale price of the Company’s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale.
The Series A 5% Convertible Preferred shares accrue annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred share. The shares of Series A 5% Convertible Preferred shares are also entitled to receive participating dividends. The shares of Series A 5% Convertible Preferred shares have no voting rights.
In the event of a liquidation, dissolution or winding up of the Company, or a deemed liquidation event, the holders of Series A 5% Convertible Preferred shares are eligible to receive the greater of (i) an amount equal to the Series A 5% Convertible Preferred original issue price, plus an amount equal to accrued and unpaid dividends thereon, or (ii) such amount per share as would have been payable had all Series A 5% Convertible Preferred shares been converted into common stock immediately prior to such liquidation, dissolution, winding up or deemed liquidation event.
The Series A 5% Convertible Preferred shares contain certain protective provisions, and require the consent of the holders of a majority of the Series A 5% Convertible Preferred Shares prior to the Company taking certain actions that would impair or reduce the rights of the Series A 5% Convertible Preferred shares, among other things; for a period of three years following the issuance date.
Please refer to the Form 8-K filed with the Securities and Exchange Commission on February 27, 2020 for further details of the Stock Purchase Agreement and related agreements.
In November 2019, the Chief Executive Officer (CEO) deposited $200,000 with the Company to be used in a proposed financing where, under the terms being negotiated, the CEO would be co-investing with Palm (and other outside investors). Ultimately, on February 28, 2020, in conjunction with the issuance of the Series A 5% Convertible Preferred shares to Palm, the funds deposited in November 2019 into the Company by the CEO were converted into shares of common stock through the Company’s At Market Issuance Sales Agreement and were included in the common stock subscribed as of February 29, 2020. A total of 78,431 shares were purchased at a purchase price of $2.85 per share, of which 70,175 were paid for from the $200,000 which had been deposited with the Company in November 2019. The additional 8,256 shares were purchased in error through the Company’s ATM broker and were paid for by the CEO.
Note 5: Geographic Information
Financial information about foreign and domestic operations and export sales is approximately as follows
|
| Nine Months Ended |
| Three Months Ended | ||||||||
| February 29, | February 28, | February 29, | February 28, | ||||||||
| Revenues from sales to unaffiliated customers: |
|
|
|
|
|
|
|
|
|
|
|
| United States | $ | 389,000 | $ | 423,000 | $ | 165,000 | $ | 141,000 | |||
| Asia |
| 1,863,000 |
|
| 1,973,000 |
|
| 404,000 |
|
| 653,000 |
| Europe | 1,226,000 | 1,330,000 | 509,000 | 416,000 | |||||||
| South America |
| 166,000 |
|
| 129,000 |
|
| 95,000 |
|
| 2,000 |
| Middle East | 313,000 | 180,000 | 4,000 | 49,000 | |||||||
| Other |
| 11,000 |
|
| -- |
|
| -- |
|
| -- |
| $ | 3,968,000 | $ | 4,035,000 | $ | 1,177,000 | $ | 1,261,000 | ||||
No other geographic concentrations exist where net sales exceed 10% of total net sales.
As of February 29, 2020 and May 31, 2019, approximately $629,000 and $665,000, of Biomerica’s gross inventory and approximately $33,000 and $39,000, of Biomerica’s property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.
Note 6: Leases
On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. The initial base rent was set at $18,490 per month with scheduled annual increases through the end of the lease term. In November 2015, the Company signed the First Amendment to Lease to extend the lease until August 31, 2021. The initial base rent for the lease amendment which started September 1, 2016 was $21,000 per month. As of September 1, 2019, the rent was $22,948 per month.
11
In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space with initial base rent of $2,926 per month. The rent is currently set at $3,239 per month as of November 1, 2019. The Company has a one 10-year option to renew at the end of the initial lease period. Biomerica, Inc. is not a guarantor of such lease. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process. In addition, the Company leases a small office on a month-to-month basis in Lindau, Germany, as headquarters for BioEurope GmbH, its Germany subsidiary.
Components of lease expense include fixed lease expense of approximately $257,838 for the nine months ended February 29, 2020. For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability. Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred.
| Supplemental cash flow information related to leases for the nine months ended February 29, 2020: | |||
| Operating cash flows from operating leases | $ | 233,262 | |
| Right-of-use assets obtained in exchange for new operating lease liabilities | -- | ||
| Weighted average remaining lease term (in years) | 6.52 | ||
| Weighted average discount rate | 6.5 | % |
The maturity of lease liabilities as of February 29, 2020 are as follows:
| Years Ending May 31 | ||
| 2020 | $ | 49,142 |
| 2021 | 211,946 | |
| 2022 |
| 236,410 |
| 2023 | 262,830 | |
| 2024 |
| 291,350 |
| Thereafter |
| 778,807 |
| Total | $ | 1,830,485 |
Note 7: Commitments and Contingencies
On December 1, 2017, Biomerica, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “At Market Issuance Sales Agreement”) with an agent (“Agent”), pursuant to which the Company may offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company’s common stock, par value $0.08 per share (the “Placement Shares”), through the Agent.
The Placement Shares have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on December 1, 2017.
Sales of the Placement Shares, if any, pursuant to the At Market Issuance Sales Agreement, may be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act. The Agent will act as sales agent and will use commercially reasonable efforts to sell on the Company’s behalf all of the Placement Shares requested to be sold by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the Agent and the Company.
12
The Company has no obligation to sell any of the Placement Shares under the At Market Issuance Sales Agreement, and may at any time suspend offers under the At Market Issuance Sales Agreement or terminate the At Market Issuance Sales Agreement. The Company intends to use the net proceeds from this offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.
Placement Shares sold during the nine months and the three months ended February 29, 2020 total 552,792 shares and 433,015 shares, respectively. Total net proceeds from the sale of Placement Shares during the nine months and the three months ended February 29, 2020 were $366,258 and $58,572, respectively. In addition, there was a subscription receivable of $1,156,311 for the sale of 418,281 Placement Shares that were sold on February 28, 2020 for which funds had not been received as of February 29, 2020. These shares were included in the 552,792 and 433,015 shares mentioned above.
On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000.
In September 2019, the Company agreed to extend MaxHealth Medical International, Limited and MaxHealth Medical Group Co., Ltd.’s option to purchase up to 500,000 shares of Biomerica’s common stock for an additional 90 days at terms described in the agreement signed May 19, 2019. This option expired at the end of December 2019.
On September 25, 2019, the Company entered into a Clinical Trial Agreement with a large, multi-physician medical group for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000.
In December 2019, the Board of Directors approved the 2020 Stock Option and Incentive Plan. The Plan is for the issuance of 900,000 options to purchase the Company’s common stock from time to time at the discretion of the Board of Directors. The Plan will be submitted for approval by the shareholders in December 2020.
In December 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $57,800.
On February 21, 2020, Biomerica, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Palm Global Small Cap Master Fund LP (“Palm”) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company’s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price (the “Purchase Price”) of approximately $2 million, or $3.50 per Series A Preferred Share (such transaction, the “Share Issuance”). The Company incurred approximately $82,000 in issuance costs associated with this stock purchase.
See Note 4, Shareholders’ Equity for further details of this transaction.
13
Note 8: Subsequent Events
Subsequent to February 29, 2020 the Coronovirus pandemic, which started in China at the end of 2019, has spread throughout the world, including the U.S. The impact it will have on the Company’s operations is unknown at this time. The Company may face supply chain disruptions, loss of contracts and/or customers, closure of the Company’s manufacturing or distribution facilities or of the facilities of the Company’s partners and customers, travel, shipping and logistical disruptions, government responses of all types, international business risks in countries where the Company makes and/or sells its products, loss of human capital or personnel at the Company, its partners and its customers, interruptions of production, customer credit risk, and general economic calamities.
On March 17, 2020, the Company announced it had commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (qualitative membrane-based immunoassay for the detection of IgG and IgM antibodies to SARS-CoV-2 in whole blood or serum) to countries outside the US for evaluation. The test is a finger prick blood test that the Company expects will show results in approximately 10 minutes and can be performed by trained professionals at any location, including airports, schools, work, pharmacies and doctors’ offices. The evaluation test kits have been requested by Ministries of Health in multiple countries through our distribution partners who are working with their government agencies to assess the tests and forecast demand. In addition, the Company has begun the application process with the FDA under the COVID-19 Emergency Use Authorization aimed at the possible clearance and eventual use of the test in the US.
On March 20, 2020, the Company filed a prospectus supplement to the base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the At Market Issuance Agreement. The Company has no obligation to sell any of the Placement Shares under the At Market Issuance Sales Agreement, and may at any time suspend offers under the At Market Issuance Sales Agreement or terminate the At Market Issuance Sales Agreement. The Company intends to use the net proceeds from this offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.
Subsequent to February 29, 2020 and through April 14, 2020, the Company sold 716,335 shares of common stock through the At Market Issuance Sales Agreement. Net proceeds to the Company were approximately $5,391,000.
Subsequent to February 29, 2020, 28,500 stock options were exercised at prices ranging from $0.82 to $3.62 per share. Net proceeds to the Company were approximately $41,740.
On March 23, 2020, Palm elected to convert 250,000 shares of Series A Convertible Preferred Stock to 250,000 shares of common stock. There were no costs for the conversion.
On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the “License Agreements”) with the Mount Sinai Icahn School of Medicine in New York (“Mount Sinai”) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus. This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States. The non-exclusive License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the License Agreements.
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EXCEPT FOR HISTORICAL INFORMATION CONTAINED HEREIN, THE STATEMENTS IN THIS FORM 10-Q MAY BE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 27A OF THE SECURITIES ACT OF 1933. FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES WHICH MAY CAUSE BIOMERICA'S RESULTS IN FUTURE PERIODS TO DIFFER MATERIALLY FROM FORECASTED RESULTS. THESE RISKS AND UNCERTAINTIES INCLUDE, AMONG OTHER THINGS, THE CONTINUED DEMAND FOR THE COMPANY'S PRODUCTS, AVAILABILITY OF RAW MATERIALS, THE STATE OF THE ECONOMY, RESULTS OF RESEARCH AND DEVELOPMENT ACTIVITIES AND THE CONTINUED ABILITY OF THE COMPANY TO MAINTAIN THE LICENSES AND APPROVALS REQUIRED. THESE AND OTHER RISKS ARE DESCRIBED IN THE COMPANY'S ANNUAL REPORT ON FORM 10-K AND IN THE COMPANY'S OTHER FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. PLEASE REFER TO THE ACCOMPANYING RISK FACTORS UNDER ITEM 1A OF THIS REPORT AS WELL AS MORE EXTENSIVE RISK FACTORS AS DESCRIBED IN THE COMPANY’S REPORT ON FORM 10K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 29, 2019.
14
IN ADDITION TO THE ABOVE, THE COMPANY ALSO HAS RISKS PERTAINING TO THE CORONAVIRUS PANDEMIC OR ANY FUTURE PANDEMIC, AND THE SOCIETAL, GOVERNMENT AND INDIVIDUAL RESPONSES TO THIS PANDEMIC. THESE RISKS INCLUDE, BUT ARE NOT LIMITED TO, SUPPLY CHAIN DISRUPTIONS, LOSS OF CONTRACTS AND/OR CUSTOMERS, CLOSURE OF THE COMPANY’S MANUFACTURING OR DISTRIBUTION FACILITIES OR OF THE FACILITIES OF THE COMPANY’S PARTNERS AND CUSTOMERS, TRAVEL, SHIPPING AND LOGISTICAL DISRUPTIONS, GOVERNMENT RESPONSES OF ALL TYPES, INTERNATIONAL BUSINESS RISKS IN COUNTRIES WHERE THE COMPANY MAKES AND/OR SELLS ITS PRODUCTS, LOSS OF HUMAN CAPITAL OR PERSONNEL AT THE COMPANY, ITS PARTNERS AND ITS CUSTOMERS, INTERUPTIONS OF PRODUCTION, CUSTOMER CREDIT RISK, AND GENERAL ECONOMIC CALAMITIES.
EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW, WE MAY NOT UPDATE OR REVISE OUR FORWARD-LOOKING STATEMENTS AND THE LACK OF SUCH UPDATE DOES NOT IMPLY THAT ACTUAL EVENTS ARE AS ORIGINALLY EXPRESSED BY SUCH FORWARD-LOOKING STATEMENTS. YOU SHOULD READ THE DISCLOSURES IN THIS REPORT AND OTHER REPORTS WHICH WE FILE WITH THE SECURITIES AND EXCHANGE COMMISSION.
OVERVIEW
Biomerica, Inc. and Subsidiaries (which includes wholly owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) develop, manufacture, and market medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. Our medical diagnostic products are sold worldwide in two markets: 1) clinical laboratories and 2) point of care (physicians' offices and over-the-counter drugstores). Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations.
RESULTS OF OPERATIONS
Consolidated net sales for Biomerica were $1,176,889 for the three months ended February 29, 2020 as compared to $1,261,161 for the three-month period ended February 28, 2019. This represents a decrease of $84,272 or 6.7%. For the nine-month period ended February 29, 2020 as compared to the nine-month period ended February 28, 2019, net sales were $3,967,712 as compared to $4,034,822. This represents a decrease of $67,110 or 1.7%. The decrease for the three-month period and for the nine-month period was primarily due to lower sales to China as a result of the coronavirus in China during the quarter ended February 29, 2020.
For the three months ended February 29, 2020 as compared to the three months ended February 28, 2019, cost of sales increased as a percentage of sales from 71.0% of sales, or $895,237, to 82.0% of sales, or $964,910. For the nine months ended February 29, 2020 as compared to February 28, 2019, cost of sales as a percentage of sales increased from 72.5% of sales, or $2,923,615 to 73.6% of sales, or $2,919,557. The increase to cost of goods as a percentage of sales for the three and nine months were due to increased material costs, higher wages and benefits’ costs as well as fixed costs in relation to lower sales during the quarter and nine months ended February 29, 2020.
For the three months ended February 29, 2020 compared to February 28, 2019, selling, general and administrative expenses increased by $77,515, or 13.5%. For the nine months ended February 29, 2020 as compared to February 28, 2019, selling, general and administrative expenses increased by $225,653, or 15.2%. The increase for the quarter and nine months ended February 29, 2020 as compared to February 28, 2019, was primarily due to an increase of non-cash option expense, and increased wages and consulting fees.
For the three months ended February 29, 2020 as compared to February 28, 2019, research and development expenses decreased by $23,823, or 4.8%. For the nine-month period ended February 29, 2020 as compared to February 28, 2019, these expenses decreased by $21,689, or 1.7%. The decrease for both periods was due in part to lower patent legal fees related to patent protection.
For the three months ended February 29, 2020 as compared to February 28, 2019, dividend and interest income increased from $28,502 to $53,964. For the nine months ended February 29, 2020 as compared to February 28, 2019, dividend and interest income increased from $40,288 to $62,515.
LIQUIDITY AND CAPITAL RESOURCES
As of February 29, 2020 and May 31, 2019, the Company had cash and cash equivalents in the amount of $2,391,732 and $686,785, and working capital of $3,829,331 and $3,230,535, respectively.
15
During the nine months ended February 29, 2020, the Company’s operations used cash of $802,911 as compared to $1,257,708 in the same period of the prior fiscal year. Cash used by operations for the nine months ended February 29, 2020 was primarily a result of a net loss of $1,852,482, which was offset by a decrease in accounts receivables of $488,759, an increase in accounts payable of $268,069, depreciation and amortization of $94,772 and stock option expense of $192,917. Cash used by operations for the nine months ended February 28, 2019 resulted from a net loss of $1,607,730 and increased receivables of $290,727 which were offset by an increase in accounts payable of $197,386 and depreciation and amortization of $128,114 and stock option expense of $146,514. The reduction in cash between the two periods primarily resulted from a decrease in accounts receivable of $488,759 for the period ended February 29, 2020 as compared to an increase in accounts receivable of $290,727 for the period ended February 28, 2019, which resulted in a $779,485 increase in fiscal 2020 versus 2019.
Cash used in investing activities in the nine months ended February 29, 2020 was $51,657, $27,724 of which was for purchases of property and equipment and $23,933 for the increase in intangibles as compared to the nine months ended February 28, 2019 during which cash used for property and equipment was $72,947 and $46,226 for the increase in intangibles. Cash provided by financing activities for the nine months ended February 29, 2020 was a result of the exercise of stock options of $79,828 and plus proceeds from the sale of common stock of $366,258, plus net proceeds from the sale of preferred stock of $1,917,586, minus the amount of common stock subscribed of $1,156,311(sales of common stock for which the proceeds were received after February 29, 2020), as compared to $82,990 from the exercise of stock options and the proceeds from the sale of common stock of $1,011,636 in the prior fiscal year nine month period.
As described in the Company’s Form 10Q and 10K reports, filed with the Securities and Exchange Commission from April 16, 2018,through November 2019 and the Form S-3 Registration Statement and Prospectus filed on June 30, 2017 and December 4, 2017, respectively, the Company entered into an At Market Issuance Sales Agreement (the “Agreement”), whereby, the Company may raise $7,000,000 in additional working capital and funds for continued development of current research projects. The Company sold shares for the full amount available for sale under the December 4, 2017 prospectus supplement as of March 18, 2020. On March 20, 2020, the Company filed a new prospectus supplement to the base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the At Market Issuance Agreement. These funds will be needed to fund current research and development projects and bring them to the next state of completion, as well as being used for general corporate purposes. Management expects to raise additional funds throughout the year from the At Market Issuance Agreement to fund operations as necessary. During the nine months that ended February 29, 2020, the Company received $366,258 in net proceeds from the sale of its common stock through this Agreement.
On February 21, 2020, Biomerica, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Palm Global Small Cap Master Fund LP (“Palm”) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company’s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price (the “Purchase Price”) of approximately $2 million, or $3.50 per Series A Preferred Share (such transaction, the “Share Issuance”). The Company incurred approximately $82,000 in issuance costs associated with this stock purchase.
The Company will use the proceeds from the sale of the Series A 5% Convertible Preferred Shares for general corporate purposes of the Company.
OFF BALANCE SHEET ARRANGEMENTS - None.
CRITICAL ACCOUNTING POLICIES
The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.
16
We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These relate to revenue recognition, bad debts, inventory overhead application, inventory reserve, lease liabilities and right-of-use assets. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial conditions or results of operations. We suggest that our significant accounting policies be read in conjunction with this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Please refer to Note 2 for information on Significant Accounting Policies.
In February 2016, the FASB issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. Leases are classified as financing or operating which will drive the expense recognition pattern. For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively. The Company has elected to exclude short-term leases. The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method. As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to the opening accumulated deficit was not required in conjunction with our adoption. For additional information, see Note 6 – Leases. We have elected not to reassess whether expired or existing contracts contain leases, nor did we reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewals options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
Item 4. CONTROLS AND PROCEDURES
Our management evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives and the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at the "reasonable assurance" level. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective to ensure that information required to be disclosed in the reports that we file and submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms; and (2) accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
There have been no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during our last fiscal quarter that has materially affected, or that is reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS. None.
Item 1A. RISKS FACTORS.
17
An investment in our common stock involves risks. Before making an investment decision, you should carefully consider all the information in this Quarterly Report, including Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations". In addition, you should carefully consider the risks and uncertainties described in the section entitled “Risk Factors,” in Part I, Item 1A, of our 2019 Annual Report on Form 10-K for the fiscal year ended May 31, 2019, filed with the Securities and Exchange Commission (SEC) on August 29, 2019 (2019 Annual Report), as well as in our other public filings with the SEC. If any of the identified risks are realized, our business, financial condition, operating results, and prospects could be materially and adversely affected. In that case, the trading price of our common stock may decline, and you could lose all or part of your investment. In addition, other risks of which we are currently unaware, or which we do not currently view as material, could have a material adverse effect on our business, financial condition, operating results, and prospects.
During the nine months ended February 29, 2020, except as specifically noted below, there were no material changes to the risks and uncertainties described in the section entitled "Risk Factors" in Part 1, Item 1A of our 2019 Annual Report.
Our business could be adversely affected by the effects of widespread public health epidemics.
We are susceptible to a widespread outbreak of an illness or other health issue, such as the recent 2019 CoV-19 Coronavirus (“Covid-19 Virus”) outbreak first reported in Wuhan, Hubei Province, China in December 2019 and subsequently spreading throughout the world resulting in hundreds of thousands of confirmed cases worldwide and many deaths. The outbreak of the Covid-19 Virus has caused the various governments, including the U.S., to implement quarantines, various restrictions on travel causing airlines to suspend international and certain domestic flights, shelter in place orders. Governments have also implemented work restrictions that prohibit many employees from going to work, and for businesses that are allowed to remain open, many employees are electing to remain at home to avoid spread of the disease. As a result of this Covid-19 Virus outbreak and potential future pandemic outbreaks, the Company faces significant risks including, but not limited to; a) supply chain disruptions making it difficult for the Company to order and receive materials needed for production of its products, and needed to ship finished products to our end customers, b) loss of contract and customers from the financial strains or other disruptions they are experiencing as a result of the pandemic, c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills, d)government responses including orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods, refuse to allow the Company’s product to be licensed for sale in their countries, and other seen and unforeseen actions taken by government agencies, e) absenteeism or loss of employees at our Company, or at our partner’s companies, due to health reasons or government restrictions, that are needed to develop, validate, manufacture and perform other necessary functions for our operations, f) equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable, g) litigation or government actions against the Company pertaining to existing products new products sold by the Company that are directed at limiting or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking system, limit demand for all products including those made by the Company, and many other seen and unforeseen events and circumstances, all of which could negatively impact the Company.
If our Covid-19 tests are unable to gain acceptance in the market, proves to be ineffective or less effective than expected, and/or we do not receive regulatory approvals for our COVID-19 tests, our results of operation could be materially harmed.
Although we believe that our Covid-19 tests represents promising tests for Covid-19 virus exposure, the test may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for our Covid-19 tests. Gaining acceptance in medical communities requires increasing awareness of our Covid-19 tests and its benefits. Industry professionals and regulatory agencies may not consider the results of our Covid-19 tests sufficiently accurate or effective.
Our ability to successfully market our Covid-19 tests will depend on numerous factors, including:
· our ability to demonstrate the efficacy, speed and cost of our Covid-19 tests;
· whether health care providers and governmental agencies believe our Covid-19 tests are sufficiently safe, effective, and accurate;
18
· our ability to transfer, further develop, integrate and use third-party licensed technology;
· our ability to manufacture and scale commercial products;
· regulatory approvals necessary prior to commercialization of our products; and
· whether the medical community accepts our Covid-19 tests as a supplement to, alternative to, or complimentary to, current PCR or other tests for Covid-19 infection.
In addition, each country has its own regulatory approval requirements. We would need to comply with the regulatory requirements of each country before we are permitted to sell in that country. There can be no assurance that governmental agencies, including the FDA, will provide clearance of our Covid-19 tests. Failure to achieve widespread market acceptance of our Covid-19 tests, or failure to achieve regulatory clearance of our Covid-19 tests, could materially harm our business, financial condition, and results of operations. Our Covid-19 tests are new tests that has not yet generated any revenue and may not result in any revenue for us.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None.
Item 3. DEFAULTS UPON SENIOR SECURITIES. None.
Item 4. MINE SAFETY DISCLOSURES. None.
Item 5. OTHER INFORMATION.
We held our Annual Meeting of Stockholders on December 11, 2019, to consider and vote on the proposals set forth in our proxy statement filed with the Securities and Exchange Commission on September 28, 2019. Please refer to the Form 8-K filed on December 13, 2019 for a description of the results of the meeting.
Item 6. EXHIBITS.
The following exhibits are filed or furnished as part of this quarterly report on Form 10-Q:
|
|
|
|
|
| ||
| Exhibit No. |
| Description | ||||
|
|
|
|
|
| ||
|
| 31.1 | * |
| Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Zackary S. Irani | ||
|
|
|
|
|
| ||
|
| 31.2 | * |
| Certification Pursuant to Section 302 of the Sarbanes-Oxley Act — Janet Moore | ||
|
|
|
|
|
| ||
|
| 32.1 | * |
| Certification Pursuant to Section 906 of the Sarbanes-Oxley Act — Zackary S. Irani | ||
|
|
|
|
|
| ||
|
| 32.2 | * |
| Certification Pursuant to Section 906 of the Sarbanes-Oxley Act — Janet Moore
| ||
| 101 | Interactive data files pursuant to Rule 405 Regulation S-T, as follows: | |||||
|
|
|
| ||||
|
|
| 101.INS-XBRL Instance Document | ||||
|
|
| 101.SCH-XBRL Taxonomy Extension Schema Document 101.CAL-XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF–XBRL Taxonomy Extension Definition Linkbase Document 101.LAB-XBRL Taxonomy Extension Label Linkbase Document 101.PRE-XBRL Taxonomy Extension Presentation Linkbase Document | ||||
|
|
|
| ||||
| * | Filed herewith | |||||
19
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has fully caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BIOMERICA, INC. | ||
| Date: April 14, 2020 | ||
|
| By: | /S/ Zackary Irani |
| Zackary S. Irani | ||
|
| Chief Executive Officer | |
|
| (Principal Executive Officer) | |
| Date: April 14, 2020 | ||
|
| By: | /S/ Janet Moore |
| Janet Moore | ||
|
| Chief Financial Officer | |
|
| (Principal Financial Officer) | |
20
Exhibit 31.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Zackary S. Irani, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Biomerica, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or other persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| Date: April 14, 2020 |
| /s/ Zackary Irani |
| Zackary S. Irani |
| Chief Executive Officer |
| (Principal Executive Officer) |
EXHIBIT 31.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Janet Moore, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Biomerica, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of our internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or other persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| Date: April 14, 2020 |
| /s/ Janet Moore |
| Janet Moore |
| Chief Financial Officer |
| (Principal Financial Officer) |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Biomerica, Inc. (the "Company") on Form 10-Q for the period ending February 29, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Zackary Irani, Chief Executive Officer of the Company, certify, to the best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002,
i.
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and
ii.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ Zackary Irani |
| Zackary S. Irani |
| Chief Executive Officer |
| Date: April 14, 2020 |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Biomerica, Inc. (the "Company") on Form 10-Q for the period ending February 29, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Janet Moore, Chief Financial Officer of the Company, certify, to the best of my knowledge, Pursuant to Exchange Act Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002,
i.
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, and
ii.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ Janet Moore |
| Janet Moore |
| Chief Financial Officer |
| Date: April 14, 2020 |